Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on January 26, 2022. The filing addresses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and the appointment of interim and permanent successors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensatory arrangements.
Material Changes
- Resignation: Marc Grasso, M.D., resigned as Chief Financial Officer, Chief Business Officer, principal accounting officer, and principal financial officer, effective February 4, 2022.
- Advisory Role: Dr. Grasso will provide advisory services for up to three months post-resignation, during which his outstanding equity awards will continue to vest.
- Appointments: On January 31, 2022, the Board appointed Thomas Doyle as Senior Vice President, Finance and Accounting, and principal accounting officer. Troy E. Wilson, Ph.D., J.D. (CEO) was appointed principal financial officer. Both appointments are effective February 7, 2022.
Compensatory Arrangements and Outlook
The filing details the new employment agreement for Thomas Doyle, effective January 31, 2022:
- Base Salary: $333,500 annually.
- Bonus: Eligible for an annual discretionary bonus of up to 35% of base salary.
- Equity Grants:
- Option to purchase 39,281 shares, vesting in 48 equal monthly installments starting February 7, 2022.
- Restricted Stock Unit (RSU) award for 8,390 shares, vesting in four equal annual installments starting January 26, 2022.
- Severance Provisions: In the event of termination without cause or resignation for good reason, Mr. Doyle is entitled to nine months of base salary and COBRA premiums. If such termination occurs within 12 months of a corporate transaction, he is also entitled to his full target bonus amount.
The filing does not contain forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook beyond the personnel changes.
Investor Verification Checklist
- Verify the effective dates of the leadership transition (February 4, 2022, for resignation; February 7, 2022, for new appointments).
- Confirm the vesting schedules for the new equity awards granted to Thomas Doyle.
- Review the specific conditions triggering the enhanced severance package (corporate transaction timing) for the new SVP of Finance.
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer, as the CEO is currently serving as the principal financial officer.